Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection

Trentini, Monalisa Martins; Oliveira, Fábio Muniz de; Gaeti, Marilisa Pedroso Nogueira; Batista, Aline Carvalho; Lima, Eliana Martins; Kipnis, André; Junqueira-Kipnis, Ana Paula

doi:10.1016/j.vaccine.2014.06.037

Cited by 10 publications

(9 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes as a versatile VADS suit various immunization routes, including mainly four ways: injection (such as intramuscular, intradermal, subcutaneous, intraperitoneal and intravenous injection), topical administration (such as cutaneous and mucosal administration); oral uptake [30], and inhalation [129]. Three reasons drive researchers to explore different immunization routes: satisfying dosage form requirement; offering convenient administration; and, most importantly, improving efficacy.…”

Section: Vaccination Routementioning

confidence: 99%

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Wang

Chen

Wang

2019

Journal of Controlled Release

198

155

View full text Add to dashboard Cite

Section: Vaccination Routementioning

confidence: 99%

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Wang

Chen

Wang

2019

Journal of Controlled Release

198

155

View full text Add to dashboard Cite

“…M72/AS01, compared to M72/AS02 and Mtb72F/AS01 vaccinations, induces greater cell‐mediated immunity in M. tb ‐negative patients 92 . Hybrid 1 (IC31) consists of antigens Ag85b and ESAT‐6 and is used in comparison to the adjuvant IC31 in cationic peptides containing CpG‐DNA 89 . This vaccine targets antigens that M. tb does not express during its latent period, though they produce excellent immune responses 94 …”

Section: Liposomal Subunit Vaccines Against Tbmentioning

confidence: 99%

Liposomal delivery system/adjuvant for tuberculosis vaccine

Moradi

Vahedi

Abbassioun

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

As reported by the World Health Organization, about 10 million individuals were infected with tuberculosis (TB) worldwide. Moreover, approximately 1.5 million people died of TB, of which 214,000 were infected with HIV simultaneously. Due to the high infection rate, the need for effective TB vaccination is highly felt. Until now, various methodologies have been proposed for the development of a protein subunit vaccine for TB. These vaccines have shown higher protection than other vaccines, particularly the Bacillus culture vaccine. The delivery system and safety regulator are common characteristics of effective adjuvants in TB vaccines and the clinical trial stage.The present study investigates the current state of TB adjuvant research focusing on the liposomal adjuvant system. Based on our findings, the liposomal system is a safe and efficient adjuvant from nanosize to microsize for vaccinations against TB, other intracellular infections, and malignancies. Clinical studies can provide valuable feedback for developing novel TB adjuvants, which ultimately enhance the impact of adjuvants on next-generation TB vaccines.

show abstract

“…As a vaccine delivery carrier, they protect antigens from degradation, carry simple or multiple hydrophilic and lipophilic antigens, control the release of the antigens, enhance cellular uptake, and improve antigen-specific immune response (Machhi et al, 2021). It suits different immunization routes including injection, topical administration, oral uptake, and inhalation (Trentini et al, 2014;Wang et al, 2014). Several lipids possess strong adjuvant activity, specially dimethyldioctadecylammonium bromide, a cationic lipid that showed the deposition of the antigen at the injection site, cellular antigen internalization, an antigen association (Anderluzzi et al, 2021).…”

Section: Lipid-based Nanoparticlesmentioning

confidence: 99%

Microemulsion Based Nanostructures for Drug Delivery

Arredondo-Ochoa

Silva-Martínez

2022

Front. Nanotechnol.

View full text Add to dashboard Cite

Most of the active pharmaceutical compounds are often prone to display low bioavailability and biological degradation represents an important drawback. Due to the above, the development of a drug delivery system (DDS) that enables the introduction of a pharmaceutical compound through the body to achieve a therapeutic effect in a controlled manner is an expanding application. Henceforth, new strategies have been developed to control several parameters considered essential for enhancing delivery of drugs. Nanostructure synthesis by microemulsions (ME) consist of enclosing a substance within a wall material at the nanoscale level, allowing to control the size and surface area of the resulting particle. This nanotechnology has shown the importance on targeted drug delivery to improve their stability by protecting a bioactive compound from an adverse environment, enhanced bioavailability as well as controlled release. Thus, a lower dose administration could be achieved by minimizing systemic side effects and decreasing toxicity. This review will focus on describing the different biocompatible nanostructures synthesized by ME as controlled DDS for therapeutic purposes.

show abstract

Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection

Abstract: We have thus demonstrated, for the first time, the use of microstructured liposomes as an adjuvant and delivery system for a vaccine formulation against tuberculosis.

Cited by 10 publications

References 55 publications

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Liposomal delivery system/adjuvant for tuberculosis vaccine

Microemulsion Based Nanostructures for Drug Delivery

Contact Info

Product

Resources

About